Limiting inflammation by inhibiting PAI-1 has been shown to be useful in cardiovascular diseases (Vaughan et al., 1997; Brown et al., 1999) and could be administered prophylactically to patients confirmed with HCPS. This evidence concerns the gene SERPINE1 and cardiovascular disorder.